Медицинская литература. Новинки

 

 

 

 

 

 

Применение гадоксетовой кислоты (Примовист®) для диагностики очаговых заболеваний печени: имеющиеся достижения и возможности дальнейшего улучшение протокола полного обследования печени с помощью МРТ

Вы можете загрузить полный текст статьи в формате pdf

Рассмотрены данные об оптимизации применения гадоксетовой кислоты (Примовиста) для диагностики очаговых заболеваний печени с учетом сведений о механизмах фармакодинамики и фармакокинетики гадоксетовой кислоты в норме и при патологических состояниях. Приведены данные исследований, доказывающих преимущества МРТ с Примовистом по сравнению с МРТ с внеклеточными контрастными средствами и рентгеновской КТ с контрастным усилением при лучевой диагностике очаговых заболеваний печени.

Ключевые слова:
гадоксетовая кислота (Примовист), очаговые заболевания печени

Литература:
1. Ратников В. А., Кузнецов С. В., Савельева Т. В и др.
Магнитнорезонансная томография гепатобилиарной
системы с применением Примовиста: современное
состояние проблемы. Лучевая диагностика и терапия
2010; №1 (1): 53–63.
2. Bellin M.F., Vasile M., Precetti M.S. Currently used non-specific extracellular MR contrast media. Eur. Radiol.
2003; 13: 2688–2698.
3. Breuer J., Balzer T., Shamsi K., Carter R. Clinical experience from phase II and phase III studies for GdEOBDTPA: a new liver specific MR contrast agent. Eur. Radiol.
2003; 13 (Suppl. 2): S109.
4. Breuer Jung G.J., Poll L.W., Koch J.A. et al. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent GdEOBDTPA. Acta Radiol. 2006; 47:
15–23.
5. Bollow M., Taupitz M., Hamm B. et al. GadoliniumethoxybenzylDTPA as a hepatobiliary contrast agent for use in
MR cholangiography: results of an in vivo phase I clinical
evaluation. Eur. Radiol. 1997; 7: 126–132.
6. Carlos R.C., Hussain H.K., Song J.H., Francis I.R. Gadoliniumethoxybenzyldiethylenetriamine pentaacetic acid
as an intrabiliary contrast agent: preliminary assessment.
Am. J. Roentgenol. 2002; 179: 87–92.
7. Bluemke D.A., Sahani D., Amendola M. Efficacy and safety of MR imaging with liver specific contrast agent: U.S.
multicenter phase III study. Radiology 2005; 237: 89–98.
8. Hamm B., Mahfouz A.E., Taupitz M. et al. Liver metastases: improved detection with dynamic gadoliniumenhanced MR imaging? Radiology 1997; 202: 677–682.
9. Hamm B., Thoeni R.F., Gould R.G. et al. Focal liver lesions:
characterization with nonenhanced and dynamic contrast
material enhanced MR imaging. Radiology 1994; 190:
417–423.
10. Hamm B., Staks T., Muhler A. et al. Phase I clinical evaluation of GdEOBDTPA as a hepatobiliary MR contrast
agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785–792.
11. Lencioni R., Cioni D., Crocetti L. Magnetic resonance
imaging of liver tumors. J. Hepatol. 2004; 40: 162–171.
12. Ni Y., Marchal G., Yu J. et al. Prolonged positive contrast
enhancement with GdEOBDTPA in experimental liver
tumors: potential value in tissue characterization. J.
Magn.Reson. Imaging 1994; 4: 355–363.
13. Reimer P., Rummeny E.J., Daldrup H.E. et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with GdEOBDTPA:
preliminary results with dynamic MR imaging. Eur. Radiol.
1997; 7: 275–280.
14. Stroszczynski C., Gaffke G., Gnauck M. et al. Aktueller
Stand der MRT_Diagnostik mit leberspezifischen Kontrast
mitteln GdEOBDTPA und GdBOPTA. [Current status of
MRI diagnostics with liver specific contrast agents. GdEOB
DTPA and GdBOPTA]. Radiology 2004; 44: 1185–1191.
15. Weinmann H.J., Ebert W., Misselwintz B. et al. Tissue specific MR contrast agents. Eur.J. Radiol. 2003; 6.: 33–44.
16. Kato N., Yokawa T., Tamura A. Gadoliniumethoxybenzyl–diethylenetriaminepentaacetic acid interaction with
clinical drugs in rats. Invest. Radiol. 2002; 37: 680–684.
17. Kirchin M.A., Runge V.M. Contrast agents for magnetic
resonance imaging: safety update. Top. Magn. Reson.
Imaging 2003; 14: 426–435.
18. Marchal G., Zhang X., Ni Y. et al. Comparison between Gd
DTPA, GdEOBDTPA, and MnDPDP in induced HCC
in rats: a correlation study of MR imaging, microangiogra
phy, and histology. Magn. Reson. Imaging 1993; 11:
665–674.
19. SchuhmannGiampieri G., Schmitt H., Press W.R. et al.
Preclinical evaluation of GdEOBDTPA as a contrast
agent in MR imaging of the hepatobiliary system.
Radiology 1992; 183: 59–64.
20. Cruite I., Schroeder M., Merkle E.M., Sirlin C.B. Gadoxetate disodiumenhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic
liver. Am. J. Roentgenol. 2010; 195: 29–41.
21. Lorusso V., Pascolo L., Fernetti C. et al. Magnetic resonance contrast agents: from the bench to the patient.
Curr. Pharm. Des. 2005; 11: 4079–4098.
22. Reimer P., Balzern T. Ferucarbotran (Resovist): a new clinically approved RES specific contrast agent for contrast
enhanced MRI of the liver: properties, clinical development, and applications. Eur. Radiol. 2003; 13: 1266–1276.
23. Reimer P., Schneider G., Schima W. Hepatobiliary contrast agents for contrast enhanced MRI of the liver: properties, clinical development and applications. Eur. Radiol.
2004; 14: 559–578.
24. Ringe K.I., Husarik D.B., Sirlin C.B., Merkle E.M. Gadoxetate disodiumenhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic
liver. Am. J. Roentgenol 2010; 195: 13–28.
25. Primovist. Product monograph. Berlin: Bayer Schering
Pharma AG; 2008. 1–40.
26. Primovist. Liver specific hepatobiliary contrast agent for
MRI of focal liver lesions: deteсtion and characterization in
single work up. Berlin: Schering AG; 2005. 1–36.
27. Bellin M.F., Webb, J., Van Der Molen A. et al. Safety of MR
liver specific contrast media. Eur. Radiol. 2005; 15:
1607–1614.
28. Zech C.J., Gschwend V. Multicenter, randomized com
parison study to evaluate outcomes and resource needs
of imaging and treatment following Primovistenhanced
MRI of the liver in comparison to extracellular contrast
mediaenhanced MRI and contrastenhanced CT in
patients with cololorectal cancer and suspected metachronous liver metastases: an interim analysis., Insights
into Imaging, ECR 2011 Book of Abstracts 2011; 2
(Suppl. 1): B223, 53.
29. Zech C.J., Grazioli L., Jonas E. et al. Healtheconomic
evaluation of three imaging strategies in patients with suspected colorectal liver metastases: GdEOBDTPA-enhanced MRI vs. extracellular contrast mediaenhanced
MRI and 3phase MDCT in Germany, Italy and Sweden.
Eur Radiol. 2009; 19 (Suppl. 3): S753–763.
30. Kolblinger C., Ssalamah A., Langle F. et al. GdEOBDTPA
enhanced MR imaging versus triphasic CT: detection and
classification of focal liver lesions. Eur. Radiol. 2006; 16
(Suppl. 1): 195.
31. Zech C.J., Grazioli L., Breuer J. et al. Diagnostic performance and description of morphological features of focal
nodular hyperplasia in GdEOBDTPAenhanced liver
magnetic resonance imaging: results of a multicenter trial.
Invest. Radiol. 2008; 43: 504–511.
32. Hwang J., Kim S.H., Kim Y.S. et al. Gadoxetic acid-enhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable tumor of hepatocellular carcinomas treated with imageguided tumor
therapy. J. Magn. Reson. Imaging 2010; 32: 629–638.
33. Di Martino M., Marin D., Guerrisi A. et al. Intraindividual
comparison of gadoxetate disodiumenhanced MR imaging and 64section multidetector CT in the Detection of
hepatocellular carcinoma in patients with cirrhosis.
Radiology 2010; 256: 806–816.
34. Chikazawa S., Inoue A., Tanabe M. et al. An experimental
study of the optimal flip angle for hepatocellular magnetic
resonance imaging with GdEOBDTPA. Nippon
Hoshasen Gijutsu Gakkai Zasshi 2010; 20: 1474–1479.
35. Jung G., Breuer J., Poll L. et al. Imaging of hepatocellular
carcinoma using the hepatobiliary contrast agent Gd EOB
DTPA. Acta Radiol. 2006; 47: 15–23.
36. Vogl T.J., Kummel S., Hammerstingl R. et al. Liver tumors:
comparison of MR imaging with GdEOBDTPA and Gd-DTPA. Radiology 1996; 200: 59–67.
37. van Montfoort J.E., Stieger B., Meijer D.K. et al Hepatic
uptake of the magnetic resonance imaging contrast agent
gadoxetate by the organic anion transporting polypeptide
Oatp1. J. Pharmacol. Exp. Ther. 1999; 290: 153–157.
38. SchmidNrannwald C., Hermann K.A., Reiser M.F., Zech
C.J. GdEOBDTPAenhanced MRI imaging (MRI) in the
early dynamic phase: is bolus timing necessary to obtain an
optimal arterial phase for liver MRI? Insights into Imaging,
ECR 2011. Book of Abstracts 2011; 2 (Suppl. 1): B225, 53.
39. Zech C.J., Vos B., Nordell A. et al. Vascular enhancement
in early dynamic liver MR imaging in an animal model:
comparison of two injection regimen and two different
doses GdEOBDTPA (gadoxetic acid) with standard Gd-DTPA. Invest. Radiol. 2009; 44: 305–310.
40. Motosugi U., Ichikawa T., Sou H. et al. Dilution method of
gadolinium ethoxybenzyl diethylenetriaminepentaacetic
acid (GdEOBDTPA)enhanced magnetic resonance imaging (MRI). J. Magn. Reson. Imaging 2009; 30: 849–854.
41. Chou C.T., Chen Y.L., Su W.W. et al. Characterization of
cirrhotic nodules with gadoxetic acidenhanced magnetic
resonance imaging: the efficacy of hepatocytephase
imaging. J. Magn. Reson. Imaging 2010; 32: 895–902.
42. Goshima S., Kanematsu M., Watanabe H. et al. Hepatic
hemangioma and metastasis: differentiation with gadoxetate disodiumenhanced 3T MRI. Am. J. Roentgenol.
2010; 195: 941–946.
43. Tanimoto A., Lee J.M., Murakami T. et al. Consensus
report of the 2nd International Forum for Liver MRI. Eur.
Radiol. 2009; 19 (Suppl. 5): S975–989.
44. Stanca C., Jung D., Meier P.J., Kullak Ublick G.A.
Hepatocellular transport proteins and their role in liver disease. Wld J. Gastroenterol. 2001; 7: 157–169.
45. Kogita S., Imai Y., Okada M. et al. GdEOBDTPA-enhanced magnetic resonance images of hepatocellular
carcinoma: correlation with histological grading and portal
blood flow. Eur. Radiol. 2010; 20: 2405–2413.

Gadoxetic Acid (Primovist) use for Diagnostic of Focal Liver Lesions: Efficacy Evidences and Possibilities for Further Improvement of Protocol Optimization of Comprehensive Evaluation of the Liver by MRI

It has been reviewed the workflowoptimized protocol using of gadoxetic acid (Primovist) for the detection and characterization of focal hepatic lesions based on data of gadoxetate pharmacokinetic and pharmacodynamic. Characterization and detection of focal liver lesions provided by Primovistenhanced MRI is superior to that provided by MRI with extracellular contrast agents or spiral CT with contrast enhancement.

Keywords:
gadoxetic acid (Primovist), focal liver lesions.